BOSTON, April 11, 2019 (GLOBE NEWSWIRE) — Albireo Pharma, Inc.
Read moreAlbireo Announces FDA Clearance of IND to Commence Phase 2 Trial of Elobixibat for the Treatment of NAFLD/NASH
Home »
Bristol-Myers Squibb’s Novel, Oral, Selective TYK2 Inhibitor Delivered Significant Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis in Phase 2 Trial
PRINCETON, N.J.–(BUSINESS WIRE)– September 12, 2018 — Bristol-Myers Squibb Company
Read more